Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis

Nintedanib is a multi‐target receptor tyrosine kinase inhibitor that reduces the decline in forced vital capacity (FVC) and prevents acute exacerbations in idiopathic pulmonary fibrosis (IPF), which is a risk factor for lung cancer. However, it remains unclear whether nintedanib is an effective trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kai, Yoshiro, Matsuda, Masayuki, Fukuoka, Atsuhiko, Hontsu, Shigeto, Yamauchi, Motoo, Yoshikawa, Masanori, Muro, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088921/
https://www.ncbi.nlm.nih.gov/pubmed/33742758
http://dx.doi.org/10.1111/1759-7714.13935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088921/
https://www.ncbi.nlm.nih.gov/pubmed/33742758
http://dx.doi.org/10.1111/1759-7714.13935

Ejemplares similares